Products & Services

Our Products and Services

See how bioAffinity Technologies is innovating the future of lung disease detection.

CyPath® Lung
Precision Pathology Laboratory Services

Contact Us
(210) 698-5334
info@bioaffinitytech.com
3300 Nacogdoches Road, Suite 216
San Antonio, TX 78217

Find us on X.com

Find us on LinkedIn
Our Science

Our Science

See how we’re harnessing flow cytometry +AI to improve lives.

Pipeline
Medical & Scientific Advisory Board
Publications & Scientific Presentations

Contact Us
(210) 698-5334
info@bioaffinitytech.com
3300 Nacogdoches Road, Suite 216
San Antonio, TX 78217

Find us on X.com

Find us on LinkedIn
About

About bioAffinity Technologies

Learn more about bioAffinity Technologies.

Executive Management
Board of Directors
Company History
Statement from the CEO

Contact Us
(210) 698-5334
info@bioaffinitytech.com
3300 Nacogdoches Road, Suite 216
San Antonio, TX 78217

Find us on X.com

Find us on LinkedIn
News & Videos

News & Videos

See what’s happening at bioAffinity Technologies.

Press Releases
News Articles
Newsletters
Videos

Contact Us
(210) 698-5334
info@bioaffinitytech.com
3300 Nacogdoches Road, Suite 216
San Antonio, TX 78217

Find us on X.com

Find us on LinkedIn
Investors

Contact Us

Contact bioAffinity

Reach out and let us know how we can help.

Executive Offices
Laboratories
Sales
Corporate Communications & Investor Relations

Contact Us
(210) 698-5334
info@bioaffinitytech.com
3300 Nacogdoches Road, Suite 216
San Antonio, TX 78217

Find us on X.com

Find us on LinkedIn

Videos

Case Study Videos

Negative CyPath® Lung Test Result Prevented High-risk Biopsy

Positive CyPath® Lung Test Result Aided Diagnosis of Recurrent Breast Cancer

Positive CyPath® Lung Test Result Led to Diagnosis of 2nd Primary Cancer

Positive CyPath® Lung Test Result Convinced Radiologist to Start Treatment in Patient with Prior Lung Cancer

Positive CyPath® Lung Test Result Led to Diagnosis of Lung Cancer at Earliest Stage 1A

“I can sleep at night and not worry that maybe I’m missing a malignancy…” Daya Nadarajah, MD

“Not every single nodule needs a biopsy…” Sai Karan “Vamsi” Guda, DO

“I needed a real-time test…that could tell me there is a tumor cell.” Gordon Downie, MD, PhD

“Lung cancer can happen anywhere, and the trick is finding it sooner than later.” Gregory White, MD

Negative CyPath® Lung Test Result Prevented Biopsy

Helpful Videos

CyPath® Lung: Advanced Early Lung Cancer Detection

The Company’s Why: President & CEO Maria Zannes discusses the origins of the company and why we are dedicated to the early diagnosis and treatment of cancer

Introducing CyPath® Lung

Israel Elias Garcia, MSN discuses the benefits of CyPath® Lung

Our Products and Services

Our Science

About bioAffinity Technologies

News & Videos

Contact bioAffinity

Videos

Case Study Videos

Negative CyPath® Lung Test Result Prevented High-risk Biopsy

Positive CyPath® Lung Test Result Aided Diagnosis of Recurrent Breast Cancer

Positive CyPath® Lung Test Result Led to Diagnosis of 2nd Primary Cancer

Positive CyPath® Lung Test Result Convinced Radiologist to Start Treatment in Patient with Prior Lung Cancer

Positive CyPath® Lung Test Result Led to Diagnosis of Lung Cancer at Earliest Stage 1A

“I can sleep at night and not worry that maybe I’m missing a malignancy…” Daya Nadarajah, MD

“Not every single nodule needs a biopsy…” Sai Karan “Vamsi” Guda, DO

“I needed a real-time test…that could tell me there is a tumor cell.” Gordon Downie, MD, PhD

“Lung cancer can happen anywhere, and the trick is finding it sooner than later.” Gregory White, MD

Negative CyPath® Lung Test Result Prevented Biopsy

Helpful Videos

CyPath® Lung: Advanced Early Lung Cancer Detection

The Company’s Why: President & CEO Maria Zannes discusses the origins of the company and why we are dedicated to the early diagnosis and treatment of cancer

Introducing CyPath® Lung

Israel Elias Garcia, MSN discuses the benefits of CyPath® Lung

Recent News

bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test

bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

View Our Products and Services

Discover Our Science

Meet bioAffinity Technologies

Browse News and Videos

View Investor Relations